PLRZNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Polyrizon Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026

$9.69−0.31 (-3.15%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): 2.0
Dividend yield: –

Polyrizon Ltd. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash & Equivalents	1.31	2.55	0.00	0.04	0.52
Short-Term Investments	–	–	0.04	–	–
Cash & Short-Term Investments	1.31	2.55	0.04	0.04	0.52
Prepaid Expenses & Other	0.22	0.00	–	–	–
Other Current Assets	0.40	0.10	0.01	–	–
Total Current Assets	13	2.65	0.05	–	–
Property, Plant & Equipment	0.01	0.01	0.01	–	–
Intangible Assets	2.55	2.88	–	–	–
Total Assets	21	5.55	0.56	–	–
Accounts Payable	0.29	0.22	0.16	–	–
Total Current Liabilities	0.44	0.26	0.50	–	–
Total Liabilities	0.44	0.26	0.75	–	–
Additional Paid-In Capital	29	10	3.53	–	–
Retained Earnings	-8.40	-5.07	-3.52	–	–
Shareholders' Equity	21	5.29	-0.19	-0.90	-0.25
Total Equity	21	5.29	-0.19	-0.90	-0.25
Total Liabilities & Equity	21	5.55	0.56	–	–
Shares Outstanding(shares)	1.61	0.00	0.43	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -25.4%

Financial strength

Current ratio: 36.37
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1877.2%

Valuation

P/E ratio: 2.0
Price to sales: –
Price to book: –
Dividend yield: –